These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 29295764)

  • 21. Substrate reduction therapies for mucopolysaccharidoses.
    Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
    Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
    Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
    Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
    Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art.
    Consiglieri G; Bernardo ME; Brunetti-Pierri N; Aiuti A
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):865-878. PubMed ID: 35773049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome editing in mucopolysaccharidoses and mucolipidoses.
    Santos HS; Poletto E; Schuh R; Matte U; Baldo G
    Prog Mol Biol Transl Sci; 2021; 182():327-351. PubMed ID: 34175047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.
    Pearse Y; Iacovino M
    Med Res Arch; 2020 Feb; 8(2):. PubMed ID: 32733997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update in the Mucopolysaccharidoses.
    McBride KL; Flanigan KM
    Semin Pediatr Neurol; 2021 Apr; 37():100874. PubMed ID: 33892850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models.
    Ellinwood NM; Vite CH; Haskins ME
    J Gene Med; 2004 May; 6(5):481-506. PubMed ID: 15133760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses.
    Rapoport DM; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():49-54. PubMed ID: 28964643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications.
    Pierzynowska K; Gaffke L; Cyske Z; Węgrzyn G; Buttari B; Profumo E; Saso L
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.
    Sato Y; Okuyama T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches.
    Fraldi A; Serafini M; Sorrentino NC; Gentner B; Aiuti A; Bernardo ME
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):130. PubMed ID: 30442177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies.
    de Ruijter J; Valstar MJ; Wijburg FA
    Curr Pharm Biotechnol; 2011 Jun; 12(6):923-30. PubMed ID: 21235449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
    Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
    Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
    Pan D
    Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique medical issues in adult patients with mucopolysaccharidoses.
    Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
    Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
    Kakkis E; Marsden D
    Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.